Neuroblastoma is a highly heterogenous cancer of childhood. High-risk disease has a poor prognosis with survival around 50% and cured patients suffer treatment related late effects. Better therapy is needed. Increased knowledge of the molecular biology of high-risk neuroblastomas is essential to devise new treatments. High-risk neuroblastomas are frequently MYCN-amplified (MNA). MNA is correlated ...